Tumors are often heterogeneous, being composed of multiple cell types with different phenotypic and molecular properties. Cancer stem-like cells (CSCs) are a highly tumorigenic cell type found in developmentally diverse tumors or cancer cell lines, and they are often resistant to standard chemotherapeutic drugs. The origins of CSCs and their relationships to nonstem cancer cells (NSCCs) are poorly understood. In an inducible breast oncogenesis model, CSCs are generated from nontransformed cells at a specific time during the transformation process, but CSC formation is not required for transformation. MicroRNA profiles indicate that CSCs and NSCCs are related, but different cell types arising from a common nontransformed population. Interestingly, medium from the transformed population stimulates NSCCs to become CSCs, and conversion of NSCCs to CSCs occurs in mouse xenografts. Furthermore, IL6 is sufficient to convert NSCCs to CSCs in genetically different breast cell lines, human breast tumors, and a prostate cell line. Thus, breast and prostate CSCs and NSCCs do not represent distinct epigenetic states, and these CSCs do not behave as or arise from classic stem cells. Instead, tumor heterogeneity involves a dynamic equilibrium between CSCs and NSCCs mediated by IL6 and activation of the inflammatory feedback loop required for oncogenesis. This dynamic equilibrium provides an additional rationale for combining conventional chemotherapy with metformin, which selectively inhibits CSCs. cellular transformation | inflammation | cancer stem cells equilibrium
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In some tumors, it has been suggested that CSCs arise as mutated versions of normal adult stem cells, whereupon they can induce tumor formation and differentiate into the various cell types within the tumor. Alternatively, CSCs might represent a specific stage along the multistep mutational process by which normal, differentiated cells become transformed. In this view, it is often thought that CSCs are precursors of differentiated cancer cells (NSCCs), but it is also possible that CSCs are derived from NSCCs or arise independently. In established cancer cell lines, the proportion of CSCs remains constant over multiple generations, but the basis of this phenomenon is unknown.
Here, we address these questions using an inducible model of oncogenesis that involves nontransformed mammary epithelial cells (MCF-10A) containing ligand-binding domain of estrogen receptor (ER-Src), a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (21, 23) . Treatment of such cells with tamoxifen (TAM) rapidly induces Src, and transformation occurs within 24-36 h, thereby making it possible to kinetically follow the transition between normal and transformed cells. Transformation is initiated by a transient inflammatory signal that causes an epigenetic switch from stably nontransformed to stably transformed cells (21) . This epigenetic switch is mediated by a positive feedback loop involving NF-κB, Lin28, Let-7 microRNA, and IL6 (21) as well as STAT3, miR-21, miR-181b-1, PTEN, and CYLD (24) . low subpopulation is capable of forming selfrenewing mammospheres (Fig. 1A) , and it generates tumors at high frequency in mouse xenografts (Fig. 1B) . In contrast, the remaining 90% of the transformed population express low levels of CD44 and high levels of CD24 (CD44 low /CD24 high ), are unable to form mammospheres and are 100-fold less efficient at causing tumors in mouse xenografts. As observed in human breast cancers (25) , the CSC population is more resistant to treatment with chemotherapeutic agents (doxorubicin, paclitaxel, 5-fluorouracil) than the non-CSC population (Fig. 1C) . Thus, the transformed population consists of a minority population of CSCs and a majority population of nonstem cancer cells (NSCCs).
Results
The above results suggest that CSCs can be generated directly from nontransformed cells during the process of cellular transformation. To test this hypothesis and exclude the possibility that a small preexisting CSC population was selectively enriched during the 36-h TAM treatment, we performed a kinetic analysis of CSC formation. CSCs (defined as CD44 high /CD24 low cells) are not observed up to 16 h after the induction of cellular transformation, but they represent 10% of the population 24 h after induction (Fig. 1D) variety of genetically distinct breast cancer cell lines (26) . Thus, CSCs can be derived directly from nontransformed cells at a specific time during the process of cellular transformation, and the proportion of CSCs within the transformed population is stable over multiple generations.
CSCs and NSCCs Generated During the Transformation Process Have Distinct MicroRNA Profiles. Although CSCs and NSCCs are formed from nontransformed cells concomitantly upon the induction of transformation, profiling of 365 microRNAs indicates that two cell populations have distinct expression patterns ( Fig. 2A) . Nineteen microRNAs are expressed at lower levels in CSCs than NSCCs, and three microRNAs are expressed at higher levels. As expected, the same set of microRNAs is also differentially expressed in mammospheres compared with the mixed transformed population ( Fig. 2A) . The miR-200 and let-7 families together with miR-145 and miR-146 are also differentially expressed in CSCs and NSCCs isolated from genetically distinct breast cancer cell lines and human breast tumors described here ( Fig. 2B and Figs. S1 and S2) and elsewhere (20) .
Importantly, the set of 22 microRNAs differentially expressed in CSCs vs. NSCCs is quite different from the set of 29 microRNAs independently shown (24) to be differentially affected in the nontransformed vs. transformed population (Fig. 2C) . Indeed, most microRNAs differentially expressed in CSCs vs. NSCCs have similar expression levels during the process of cellular transformation (i.e., at various time points after TAM addition). Conversely, most microRNAs differentially expressed during the process of cellular transformation are expressed at comparable levels in sorted CSCs and NSCCs. However, the let-7 family and miR-335 are down-regulated during transformation and further down-regulated in CSCs, whereas miR-210 is upregulated in both situations. Thus, in some respects (let-7, miR-335, and miR-210), CSCs represent a more extreme version of transformed cells and, indeed, CSCs have a more robust inflammatory feedback loop (high NF-κB, high Lin28, low let-7, and high IL6) than NSCCs (21) . More generally, however, CSCs and NSCCs represent two distinct cell types within a transformed population generated through a common induction step.
CSC Formation Depends on, but Is Not Required for, Transformation.
Cellular transformation and CSC formation are both induced upon addition of TAM to ER-Src cells, but it is unclear if one cell type is a precursor of the other or whether they arise independently. To address this issue, we took advantage of previous observations that miR-200, which is strongly down-regulated in CSCs, inhibits CSC growth and the epithelial-mesenchymal transition (27) (28) (29) (30) (31) . Addition of miR-200b before TAM treatment essentially abolishes CSC formation, but it has no detectable ef- fect on cellular transformation [assayed morphologically (22) or by colony formation in soft agar; Fig. 3A Sorted CSCs rapidly differentiate into NSCCs, such that after 9 d, the population was ∼15% CSCs and 85% NSCCs (Fig. 3B) . Over more extended times, the CSC population is maintained at the 10% level typical of the transformed cell line. In contrast, the sorted NSCCs generate very few CSCs over the same period (Fig. 3B) . Similar results were obtained with CSCs and NSCCs derived directly from a breast tumor (Fig. 3C) . Thus, although NSCCs and CSCs can form concomitantly during the process of cellular transformation, the conversion of NSCCs to CSCs is very inefficient. The failure of the sorted CSCs to be stably propagated under these conditions indicates that CSCs do not represent a stable epigenetic state.
Conversion of NSCCs to CSCs Within Tumors in Mouse Xenografts.
The nonreciprocal conversion between sorted NSCCs and CSCs should result in ever-decreasing numbers of CSCs and, hence, is paradoxical in light of the constant proportion of CSCs within the transformed population. This apparent paradox suggests that CSCs and NSCCs interact with each other in a mixed population in a manner that does not occur when the cell types are propagated separately. As a first test of this hypothesis, we performed a mixed xenograft experiment (Fig. 4A ) involving coinjection of NSCCs from an ER-negative, PKCα-positive cell line (MDA-MB-231) and CSCs from ER-Src cells (ER-positive, PKCα-negative). In comparison with tumors generated by ER-Src CSCs alone, the CSC population in the tumor derived by coinjection had 5-to 10-fold fewer ER-positive cells (assayed by ER DNA and RNA levels) and 10-fold higher PKCα-positive cells (assayed by RNA levels) (Fig. 4B) , indicating that most of the CSCs in the tumor were derived from the ER-negative NSCCs. Because injection of the same number of ER-negative NSCCs is insufficient to generate tumors (Fig. S1 ), this experiment suggests that ERnegative NSCCs can be converted to CSCs in the presence of the ER-positive CSCs during tumor formation.
IL6 Can Convert NSCCs to CSCs in Breast and Prostate Cell Lines as
Well as from Cells Derived from Human Breast Tumors. As more direct experimental support, medium from the culture of ER-Src transformed cells results in the conversion of isolated NSCCs to CSCs, with the proportion of CSCs approaching that occurring in the nonsorted population of transformed cells (Fig. 5A ). Breast CSCs have an enhanced inflammatory feedback loop compared with NSCCs (21), suggesting that the key component(s) of the medium might be a secreted inflammatory molecule. In this regard, when an antibody against IL6 is added to the medium, the conversion of NSCCs to CSCs is largely blocked, suggesting that secreted IL6 is important for generating CSCs from NSCCs. NSCCs to CSCs is also observed in a genetically different breast cancer cell line (MB-231) and in NSCCs obtained directly from five human breast tumors (Fig. 5A) . Importantly, the IL6-treated NSCCs from ER-Src, MB-231, and the five breast tumors are truly CSCs, as defined by their cell surface markers (Fig. 5A ), mRNA and microRNA profiles (Fig. 5B) , and the ability to form mammospheres (Fig. 5C ). Furthermore, s.c. injection of 50 IL6-derived CSCs from both cancer cell lines and both breast tumors tested causes tumors in nude mice (Fig. S3) ecules) that converts some NSCCs into CSCs. In this regard, the positive feedback loop involving NF-κB, Lin28, Let-7, and IL6 that links inflammation to cancer is more robust in CSCs than in NSCCs, such that CSCs express and secrete higher levels of IL6 than NSCCs (21).
To maintain a stable equilibrium, the rate of CSC differentiation is balanced by the rate of CSC formation, the latter of which depends on the proportion of CSCs in the population, the amount of IL6 secreted by CSCs, the level of IL6 receptor, and the overall response of NSCCs to the concentration of IL6. The set point for this equilibrium can differ among cell lines, thereby explaining why the proportion of CSCs varies among transformed cell lines even though it remains constant in a given cell line. Thus, although CSCs and NSCCs have different microRNA and mRNA profiles, conversion from one cell type to the other occurs fairly rapidly in both directions. The molecular mechanisms for how these different transcriptional profiles are generated from nontransformed cells or from the other transformed cell type remain to be elucidated. In any event, it is remarkable that CSCs and NSCCs exist in a dynamic equilibrium, as opposed to one cell type taking over the population, and it seems highly likely that the balanced interconversion between these distinct cell types is biologically important. More generally, the IL6-mediated conversion of NSCCs to CSCs suggests that, despite their name and phenotypic similarities, breast (and likely prostate) CSCs behave differently than classic stem cells.
Implications for Breast Cancer, the Cancer Stem Cell Hypothesis, and Combinatorial Chemotherapy Involving Metformin. The dynamic equilibrium between breast CSCs and NSCCs observed in transformed cells lines and breast tumors is likely to be relevant for heterogeneous breast cancers that contain a small number of CSCs within a large population of nontumorigenic cancer cells. We suggest that CSCs derive from NSCCs that arise from multiple mutations in oncogenes and tumor suppressors, and this conversion is required for tumor formation. Once formed, CSCs self-renew, continuously generate NSCCs via differentiation, and convert some NSCCs back into CSCs by secreting extracellular signals such as IL6 within the confines of the tumor. A similar equilibrium is observed in a prostate cell line, and it may also occur in other cancer types in which CSCs are found (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . As inflammation is associated with many cancer types (23, 32, 33) , the IL6-based mechanism may be involved in nonbreast cancers, although analogous mechanisms using other secreted molecules could perform the same function.
The cancer stem cell hypothesis suggests that standard chemotherapeutic treatment can effectively kill NSCCs, thereby dramatically reducing tumor size, but CSCs largely survive this treatment (1, 2) . As a consequence, after chemotherapy is ended, the CSCs reinitiate tumor formation and differentiate into NSCCs that make up the bulk of the tumor. In mouse xenografts, such relapse is prevented by the combination of conventional chemotherapy and metformin, which selectively kills cancer stem cells (26) . In addition, such combinatorial therapy reduces tumor growth more rapidly than chemotherapy alone (26) , and we suggest that metformin not only selectively kills existing CSCs, but that it indirectly lowers the CSC burden by inhibiting the conversion of NSCCs to CSCs. More generally, the dynamic equilibrium between CSCs and NSCCs provides an additional rationale for combining conventional chemotherapy and metformin for treatment of breast (and potentially other) cancers.
Materials and Methods
Cell Culture. The nontransformed breast cell line MCF-10A (34) contains an integrated fusion of the v-Src oncoprotein with ER-Src (35) . These cells were grown in DMEM/F12 medium supplemented with 5% donor horse serum, 20 ng/mL epidermal growth factor (EGF), 10 μg/mL insulin, 100 μg/mL hydrocortisone, 1 ng/mL cholera toxin, 50 units/mL pen/step, with the addition of puromycin. Src induction and cellular transformation was achieved by treatment of 1 μM 4-OH TAM, typically for 36 h as described (21, 23, 26 Shipitsin et al. (36) . Briefly, the breast tissues were minced into small pieces (1 mm) by using a sterile razor blade. The tissues were digested with 2 mg/mL collagenase I (C0130; Sigma) and 2 mg/mL hyalurinidase (H3506; Sigma) in 37°C for 3 h. Cells were filtered, washed with PBS, and followed by Percoll gradient centrifugation. The first purification step was to remove the immune cells by immunomagnetic purification by using an equal mix of CD45 (leukocytes), CD15 (granulocytes), CD14 (monocytes), and CD19 (B cells) Dynabeads (Invitrogen). The second purification step was to isolate fibroblasts from the cell population by using CD10 beads for magnetic purification. The third step was to isolate the endothelial cells by using an "endothelial cocktail" beads (CD31, BD Pharmingen cat no. 555444; CD146 P1H12 MCAM, BD Pharmingen cat no. 550314; CD105, Abcam cat no. Ab2529; Cadherin 5, Immunotech cat no. 1597; and CD34, BD Pharmingen cat no. 555820). In the final step, from remaining cell population, only the CD44 high cells were purified by using CD44 beads. These cells were sorted for CD44 high /CD24 low (CSC) cells. On the other hand, CD24 high cells were purified by using CD24 beads. These cells were sorted for CD44 low /CD24 high (NSCCs) cells. These CSC and NSCC populations were sorted again to increase their purity (>99.2% in all cases).
Mammosphere Formation Assay. Mammospheres were generated by placing transformed cell lines in suspension (1,000 cells per mL) in serum-free DMEM/ F12 media, supplemented with B27 (1:50, Invitrogen), 0.4% BSA, 20 ng/mL EGF, and 4 μg/mL insulin. After 6 d of incubation, mammospheres were typically >75 mM in size with ∼97% being CD44 high /CD24 low . For serial passaging, 6-d-old mammospheres were harvested by using a 70-μm cell strainer, whereupon they were dissociated to single cells with trypsin (37) , and then regrown in suspension for 6 d.
Chemotherapy Treatment of CSCs and NSCCs. CSCs and NSCCs were sorted from ER-Src transformed (36 h tam-treated) cells, seeded in monolayer culture, and treated with different doses of paclitaxel, doxorubicin, and 5-fluorouracil for 24 h and cell viability was assessed by the CCK8 assay (Dojindo).
MicroRNA Transfection Experiments. ER-Src MCF10A cells were transfected with 100 nM microRNA negative control (miR NC) or miR-200b by using siPORT . Model for formation of NSCCs and CSCs and the dynamic equilibrium between these cell types mediated by IL6. Transformation and generation of NSCCs is required for CSC formation. CSCs rapidly differentiate back into NSCCs, but they also secrete IL6 to allow conversion of NSCCs to CSCs, thereby maintaining the dynamic equilibrium.
